Author:
Esmaeli B,Diba R,Ahmadi M A,Saadati H G,Faustina M M,Shepler T R,Talpaz M,Fraunfelder R,Rios M B,Kantarjian H
Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with Philadelphia chromosome. N Engl J Med 2001; 344: 1038–1042.
2. Druker BJ, Talpaz M, Resta Debra J, Peng B, Buchdunger E, Ford JM et al. Efficacy and safety of a specific inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia. N Engl J Med 2001; 344: 1031–1037.
3. Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ . Inhibition of c-kit receptor tyrosine kinase activity by STI571: targeting BCR-ABL as therapy for CML. Oncologist 2000; 6: 925–932.
4. Mauro MJ, Druker BJ . STI571: Targeting BCR-ABL as Therapy for CML. Oncologist 2001; 6: 233–238.
5. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Di Paulo ED, Dimitrijevic S et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumors: a phase I study. Lancet 2001; 358: 1421–1423.
Cited by
50 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献